Physician profile
Michael J Pratts
NPI 1427382670
$39,703.44
in general payments reported to CMS, 2019-2025
19 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $9,774 · 2021: $152 · 2022: $34.46 · 2024: $15.15 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.57 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15,595.77 | 2019-2021 | |
| Allergan, INC. | $12,094.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11,061.41 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $157.57 | 2019-2025 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $116.60 | 2025 | Cobenfy |
| Indivior INC. | $97.76 | 2019-2020 | |
| Lundbeck LLC | $77.62 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.50 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $66.71 | 2019-2020 | |
| Abbvie INC. | $57.74 | 2021-2022 | |
| Shire North American Group INC | $49.26 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Vanda Pharmaceuticals INC. | $46.69 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $42.06 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $38.10 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $26.71 | 2025 | Qelbree |
| Alkermes, INC. | $24.26 | 2019 | |
| Neuronetics, INC. | $15.15 | 2024 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pratts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.